TG Therapeutics Announces UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Met Primary Endpoint OF Overall Response Rate In Patients With Relapsed/Refractory Marginal Zone Lymphoma
Benzinga Newsdesk